research European expert consensus statement on the systemic treatment of alopecia areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
Search
for
Sort by
Research
600-630 / 1000+ results 
research 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
Ritlecitinib effectively treats alopecia areata with manageable side effects.
research Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
research Platelet-rich plasma in the treatment of alopecia areata: A retrospective evaluation of 17 patients
PRP treatment may help with alopecia areata, especially in newer cases.
research Evaluation of fractional carbon dioxide laser alone versus its combination with betamethasone valerate in treatment of alopecia areata, a clinical and dermoscopic study
The fractional carbon dioxide laser is a safe and effective treatment for alopecia areata and works better than betamethasone valerate cream alone.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Alopecia Areata: A Complex Cytokine Driven Disease
Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.
research New Instrumentation for Hair Transplantation Surgery
New instruments were introduced to make hair transplantation surgery more precise and improve graft survival.
research Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy
Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
research Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study
Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.
research Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
Baricitinib is a safe and effective alternative for alopecia areata patients who do not respond to tofacitinib.
research Serum interleukin-37 and its gene polymorphism (rs3811047) in Egyptian patients with alopecia areata
Higher IL-37 levels are linked to more severe alopecia areata, but the gene variation doesn't affect disease risk.
research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
research Not just thinning: A case of alopecia universalis after mild COVID-19
A woman lost all her hair after mild COVID-19, but it started to regrow after treatment with a specific medication.
research The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double‐blind placebo‐controlled trial
Latanoprost 0.005% solution safely increases hair density and regrowth in scalp alopecia areata.
research Determination of serum 25-hydroxyvitamin D levels in patients with alopecia areata and their comparison with levels in healthy controls: A cross-sectional study
Patients with alopecia areata may have lower vitamin D levels than healthy people.
research Time to loss of response for dupilumab in ophiasis-pattern alopecia areata
Dupilumab helped a woman with severe hair loss regrow her hair quickly and maintain it for six months after stopping treatment.
research Cellular retinol‐binding protein‐1 expression increases with increasing clinical severity of alopecia areata
Higher CRBP1 levels are linked to more severe alopecia areata.
research Reply to: “Serum vitamin D level and disease severity of alopecia areata: A meta-regression analysis”
Low vitamin D might be one of several factors involved in the hair loss condition alopecia areata.
research A clinical study on alopecia areata
Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Assessment of Alopecia Areata Disease Severity in Pediatric Patients
New tools help doctors better assess and treat alopecia areata in kids by considering more than just hair loss.